Trial Profile
A phase IIa, single-center, randomized, reference-controlled, observer-blind trial to assess the efficacy of a topical Aescin formulation in experimentally induced itch, wheal and flare reactions in patients with type-I allergy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2015
Price :
$35
*
At a glance
- Drugs MAM 06301 (Primary) ; Dimetindene; Methylprednisolone aceponate
- Indications Grass pollen hypersensitivity; Tree pollen hypersensitivity
- Focus Therapeutic Use
- Sponsors Marinomed Biotechnologie
- 10 Sep 2015 New trial record